Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF Trap in Recurrent Malignant Glioma
NCT00369590Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Dec 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in malignant glioma, sponsored by National Cancer Institute. Primary endpoints: Progression-free Survival (PFS) at 6 Months and Safety Profile - Toxicities up to 78 weeks. Started Aug 2006; status: completed.
02
Drugs
aflibercept
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00369590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369590.